Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dacogen (decitabine) only Clear all
Completed Phase 1 Interventional

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

NCT01241162
View directory record Official record
Conditions
Neuroblastoma, Ewings Sarcoma, Osteogenic Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
Interventions
Autologous dendritic cell vaccine with adjuvant
Biological
Lead sponsor
University of Louisville
Other
Eligibility
1 Year to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional Results available

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

NCT02954653
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
PF-06747143, Cytarabine, Daunorubicin, Azacitidine, Decitabine
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Tucson, Arizona • Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional

Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

NCT02234037
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine, Exercise
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial

NCT02664181
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Nivolumab, oral decitabine, Tetrahydrouridine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
View directory record Official record
Conditions
Healthy
Interventions
Decitabine, Tetrahydrouridine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 28, 2026, 6:55 AM EDT
Active, not recruiting Phase 1 Interventional

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Dexamethasone, Palbociclib, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641
View directory record Official record
Conditions
Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
Interventions
Vemurafenib + Cobimetinib, Decitabine
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

NCT02103478
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 2 Interventional

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

NCT01993641
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS
Interventions
pracinostat, Azacitidine, Decitabine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
21
States / cities
Mobile, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

NCT03593915
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Combination Product
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Early Phase 1 Interventional

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

NCT03445858
View directory record Official record
Conditions
Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer, Refractory Cancer, Adult Solid Tumor, Adult Lymphoma
Interventions
Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation
Drug · Radiation
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 1 Interventional

KRAS Wild-type Metastatic Colorectal Cancer Trial

NCT00879385
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Dacogen™ (decitabine), Vectibix® (panitumumab)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01546038
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
PF-04449913, Low dose ARA-C (LDAC), Decitabine, Daunorubicin, Cytarabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT01177540
View directory record Official record
Conditions
Pediatric Acute Myelogenous Leukemia (AML)
Interventions
Decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Year to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Phoenix, Arizona • Madera, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

NCT03217838
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
AZD2811, Azacitidine, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 28, 2026, 6:55 AM EDT
Recruiting Phase 1 Interventional

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

NCT05190471
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Decitabine (in combination with BP1002)
Drug
Lead sponsor
Bio-Path Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

NCT02920008
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
guadecitabine, Treatment Choice (TC)
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 1 Interventional Results available

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

NCT03019003
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Oral Decitabine, Durvalumab, 5' Azacitidine, Tremelimumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 28, 2026, 6:55 AM EDT
Recruiting Phase 2 Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 28, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 28, 2026, 6:55 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03164057
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Drug · Combination Product · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
29 Days to 21 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Madera, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 28, 2026, 6:55 AM EDT
Active, not recruiting Phase 1 Interventional

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

NCT03679650
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML fusion cells
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

NCT03395873
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Avelumab
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 28, 2026, 6:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT02608268
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MBG453, PDR001, Decitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 28, 2026, 6:55 AM EDT